2024

Paiania, 19 September 2024 – Lavipharm reports an increase in consolidated sales in H1 2024. Specifically, consolidated Sales from continuing operations amounted to EUR 30.6 million, compared to EUR 29.1 million in the corresponding period of 2023, for an increase of 5.3%. Consolidated Sales, after...

Presentation to the Hellenic Fund and Asset Management Association Paiania, 24 April 2024 – Lavipharm held today its Annual Analysts Briefing, in accordance with the Company’s financial calendar for 2024. The presentation took place at the Athens Exchange to the members of the Hellenic Fund...

Paiania, 16 February 2024 - “Lavipharm S.A, pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces the Financial Calendar of 2024, as follows :   Wednesday, 28 February 2024 Flash Note Financial Results of the FY.2023 Thursday, 21 March 2024 Announcement of the FY.2023 Financial Report Wednesday, 24...

Peania, 14 February 2024 - Lavipharm S.A., in accordance with Regulation (EU) 596/2014, announces the cessation of the Group’s pharmaceutical wholesale activities and logistics services to third parties (3PL), and the transfer of certain assets of its subsidiary LAS to Profarm S.A. Special attention has...